ChromaDex Corporation

Informe acción NasdaqCM:CDXC

Capitalización de mercado: US$256.6m

Salud financiera de hoja de balance de ChromaDex

Salud financiera controles de criterios 6/6

ChromaDex tiene un patrimonio de los accionistas total de $28.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $55.0M y $26.5M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$27.17m
PatrimonioUS$28.46m
Total pasivoUS$26.51m
Activos totalesUS$54.96m

Actualizaciones recientes sobre salud financiera

Recent updates

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28
Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08
Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31
We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale

Oct 03

ChromaDex in pact to introduce anti-aging compound in Brazil

Sep 01

Ayana Bio appoints Frank Jaksch as CEO

Aug 24

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

Some ChromaDex Corporation (NASDAQ:CDXC) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 15
Some ChromaDex Corporation (NASDAQ:CDXC) Analysts Just Made A Major Cut To Next Year's Estimates

We're Not Very Worried About ChromaDex's (NASDAQ:CDXC) Cash Burn Rate

Mar 03
We're Not Very Worried About ChromaDex's (NASDAQ:CDXC) Cash Burn Rate

Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth

Nov 19
Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth

When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?

Sep 14
When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?

We Discuss Whether ChromaDex Corporation's (NASDAQ:CDXC) CEO Is Due For A Pay Rise

Jun 11
We Discuss Whether ChromaDex Corporation's (NASDAQ:CDXC) CEO Is Due For A Pay Rise

ChromaDex to sell Tru Niagen in 3,800 Walmart stores in the U.S.

Jun 07

Is There Now An Opportunity In ChromaDex Corporation (NASDAQ:CDXC)?

Jun 02
Is There Now An Opportunity In ChromaDex Corporation (NASDAQ:CDXC)?

We Think ChromaDex (NASDAQ:CDXC) Can Easily Afford To Drive Business Growth

May 14
We Think ChromaDex (NASDAQ:CDXC) Can Easily Afford To Drive Business Growth

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($49.5M) de CDXC superan a sus pasivos a corto plazo ($20.6M).

Pasivo a largo plazo: Los activos a corto plazo de CDXC ($49.5M) superan a sus pasivos a largo plazo ($5.9M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CDXC está libre de deudas.

Reducción de la deuda: CDXC no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable CDXC tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: CDXC no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 18.4% al año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target